NeoGenomics (NEO)
(Delayed Data from NSDQ)
$13.53 USD
-0.01 (-0.07%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $13.52 -0.01 (-0.07%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.53 USD
-0.01 (-0.07%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $13.52 -0.01 (-0.07%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Zacks News
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of -7.69% and 0.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers Squibb (BMY) Q4 Earnings Meet Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 0% and 0.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
NeoGenomics (NEO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and -1.67%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate NeoGenomics (NEO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 80.00% and 1.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: NeoGenomics (NEO) Q2 Earnings Expected to Decline
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Advanced Micro Devices, NeoGenomics, Microsoft, Google and Amazon highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Advanced Micro Devices, NeoGenomics, Microsoft, Google and Amazon highlighted as Zacks Bull and Bear of the Day
Bear of the Day: NeoGenomics (NEO)
by Kevin Cook
Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Moving Average Crossover Alert: NeoGenomics (NEO)
by Zacks Equity Research
NeoGenomics (NEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Zacks.com featured highlights include: HealthEquity, NeoGenomics, Howard Hughes Corp and StoneCo
by Zacks Equity Research
Zacks.com featured highlights include: HealthEquity, NeoGenomics, Howard Hughes Corp and StoneCo
Don't Let These 4 Toxic Stocks Erode Your Wealth
by Rimmi Singhi
Spotting bloated toxic stocks on a regular basis and abandoning them at the right time is one of the secrets to a winning investment strategy.
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of -500.00% and 2.62%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in NeoGenomics (NEO): Can Its 7.9% Jump Turn into More Strength?
by Zacks Equity Research
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Earnings Preview: NeoGenomics (NEO) Q4 Earnings Expected to Decline
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH